RSS

lymphoblastic leukaemia (ALL)

The US Food and Drug Administration (FDA) has approved a targeted therapy, Besponsa (inotuzumab ozogamicin), for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL). more

News

MyTomorrows and Spectrum Pharmaceuticals team up to provide access to liposome-encapsulated vincristine for the treatment of Philadelphia chromosome negative acute lymphoblastic leukaemia more

News

CTL019, is the first personalised cellular therapy for the treatment of cancer to receive this important classification. more

UK pharmaceutical firm Nova Laboratories has secured FDA approval for its acute lymphoblastic leukaemia (ALL) product Xaluprine, following a NDA to the organisation in July 2013. The drug, which will be marketed in the US as Purixan, is a 20 mg/ml... more

Technology